BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8674569)

  • 1. Estrogen and progesterone receptor content of GnRH analogue pretreated and untreated uterine leiomyomata.
    Regidor PA; Schmidt M; Callies R; Kato K; Schindler AE
    Eur J Obstet Gynecol Reprod Biol; 1995 Nov; 63(1):69-73. PubMed ID: 8674569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
    Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
    Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate.
    Rein MS; Friedman AJ; Stuart JM; MacLaughlin DT
    Fertil Steril; 1990 Jun; 53(6):1018-23. PubMed ID: 2112489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.
    Uemura T; Mori J; Yoshimura Y; Minaguchi H
    Asia Oceania J Obstet Gynaecol; 1991 Dec; 17(4):315-20. PubMed ID: 1724899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlates of leiomyoma estrogen and progesterone receptors among Nigerian women.
    Awowole IO; Makinde ON; Badejoko OO; Omoniyi-Esan GO; Tijani AM; Ajenifuja KO; Loto OM
    Int J Gynaecol Obstet; 2016 Dec; 135(3):314-318. PubMed ID: 27599599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens.
    Ichimura T; Kawamura N; Ito F; Shibata S; Minakuchi K; Tsujimura A; Umesaki N; Ogita S
    Fertil Steril; 1998 Nov; 70(5):967-71. PubMed ID: 9806586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
    Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
    Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metachromasia of the endocervical epithelium in women treated with gonadotropin releasing hormone agonist.
    Morimura M; Ishiko O; Honda KI; Sumi T; Kawamura N; Wakasa K; Haba T; Ogita S
    Int J Mol Med; 2001 Sep; 8(3):319-21. PubMed ID: 11494062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
    Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
    Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata.
    Deligdisch L; Hirschmann S; Altchek A
    Fertil Steril; 1997 May; 67(5):837-41. PubMed ID: 9130887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
    De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
    J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
    Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
    Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactive and estrogen-binding estrogen receptors, and progestin receptor levels in uterine leiomyomata and their parental myometrium.
    Chrapusta S; Konopka B; Paszko Z; Sieinski W; Szamborski J
    Eur J Gynaecol Oncol; 1990; 11(4):275-81. PubMed ID: 2245811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy.
    Dou Q; Zhao Y; Tarnuzzer RW; Rong H; Williams RS; Schultz GS; Chegini N
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3222-30. PubMed ID: 8784073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy.
    Nisolle M; Gillerot S; Casanas-Roux F; Squifflet J; Berliere M; Donnez J
    Hum Reprod; 1999 Nov; 14(11):2844-50. PubMed ID: 10548634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women.
    Vollenhoven BJ; Pearce P; Herington AC; Healy DL
    Clin Endocrinol (Oxf); 1994 Apr; 40(4):537-44. PubMed ID: 8187322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
    Lethaby A; Vollenhoven B; Sowter M
    Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.